Metoprolol Tartrate Ipca Laboratories Uk (Metoprolol Tartrate)

Metoprolol Tartrate is a selective β1‑adrenergic antagonist used in cardiovascular disease management.

• Hypertension: lowers blood pressure by reducing heart rate and cardiac output.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest pain.
• Post‑myocardial infarction: reduces risk of recurrent infarction and improves survival.
• Heart failure: improves ventricular function and reduces symptoms.
• Cardiac arrhythmias: controls heart rate in atrial fibrillation and other supraventricular tachyarrhythmias.

• Metoprolol Tartrate selectively blocks β1‑adrenergic receptors in the heart, inhibiting catecholamine‑induced stimulation. This results in decreased heart rate, reduced myocardial contractility, and lower cardiac output, which together lower arterial pressure and myocardial oxygen consumption.

Metoprolol Tartrate may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Fatigue or tiredness
• Dizziness or light‑headedness
• Cold extremities
• Bradycardia (slow heart rate)
• Gastrointestinal upset (nausea, abdominal discomfort)
• Headache

Serious or Rare Side Effects

• Severe bradycardia or heart block
• Marked hypotension
• Bronchospasm, especially in patients with asthma
• Allergic reactions (rash, angioedema)
• Depression or mood changes
• Cardiogenic shock

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Cardiovascular assessment: avoid in patients with severe bradycardia or advanced heart block.
• Respiratory conditions: use cautiously in asthma or chronic obstructive pulmonary disease.
• Diabetes monitoring: may mask hypoglycaemia symptoms; adjust glucose monitoring.
• Concomitant beta‑blockers: avoid additive negative chronotropic effects.
• Pregnancy considerations: safety category unknown; prescribe only if benefits outweigh risks.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Metoprolol Tartrate can interact with several drug classes; some combinations should be avoided, while others require close monitoring.

Major Interactions (Avoid)

• Calcium channel blockers (verapamil, diltiazem): may cause profound bradycardia.
• CYP2D6 inhibitors (quinidine, propafenone): increase metoprolol plasma levels.
• Clonidine: abrupt discontinuation after concurrent use can precipitate hypertension.
• Insulin or oral hypoglycemics: enhanced glucose‑lowering effect.
• Non‑selective beta blockers: additive negative cardiac effects.

Moderate Interactions (Monitor Closely)

• NSAIDs: may reduce antihypertensive efficacy.
• Diuretics: risk of excessive blood pressure reduction.
• Antidepressants (SSRIs, SNRIs): potential for bradycardia.
• Antithyroid drugs: may alter heart rate response.
• Anesthetic agents: increased risk of intra‑operative hypotension.